[1] 钟代曲,蒋小江,沈盈盈,等.脑卒中高危人群规范化筛查模式的建立与应用[J].重庆医学,2014,43(12):1428~1430.
[2] 林念童,杨碧萍,冼树清,等.阿替普酶动静脉溶栓治疗急性缺血性脑卒中的比较性研究[J].中华神经医学杂志,2012,11(10):1030~1033.
[3] Jauch E C, Saver J L, Adams H P, et al. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013,44(3):870~947.
[4] Saver J L, Fonarow G C, Smith E E, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke[J]. Jama, 2013, 309(23): 2480~2488.
[5] Engelter S T, Bonati L H, Lyrer P A. Intravenous thrombolysis in stroke patients of≥ 80 versus< 80 years of age-a systematic review across cohort studies[J]. Age and ageing, 2006, 35(6): 572~580.
[6] Solling C, Ashkanian M, Hjort N, et al. Feasibility and logistics of MRI before thrombolytic treatment[J]. Acta neurologica Scandinavica, 2009, 120(3): 143~149.
[7] Breuer L, Schellinger P D, Huttner H B, et al. Feasibility and safety of magnetic resonance imaging‐based thrombolysis in patients with stroke on awakening: initial single‐centre experience[J]. International Journal of Stroke, 2010, 5(2): 68~73.
[8] Tsivgoulis G, Eggers J, Ribo M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis a comprehensive review and meta-analysis of randomized and nonrandomized studies[J]. Stroke, 2010, 41(2): 280~287.
[9] 姜晋灵.静脉溶栓治疗时间窗控制对急性缺血性脑卒中疗效的影响[J].中国实用神经疾病杂志,2016,19(19):94~95.
[10] Lees K R, Bluhmki E, Von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of Ecass , Atlantis, Ninds, and Epithet trials[J]. The Lancet, 2010, 375(9727): 1695~1703.
[11] 徐敏,王泓,魏慧.高龄急性脑梗死患者58例溶栓后并发症分析与护理对策[J].中国乡村医药,2015,22(23):81~82.
[12] 郭义坤,李焰生.急性脑梗死患者重组组织型纤溶酶原激活物静脉溶栓后脑出血[J].国际脑血管病杂志,2010,18(2):113~118.
[13] Katzan I L, Cebul R D, Husak S H, et al. The effect of pneumonia on mortality among patients hospitalized for acute stroke[J]. Neurology, 2012, 60(4): 620~625. |
2018, Vol. 24 
